# Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial (CONDOR TRIAL)

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA-IRVINE · 2023 · $314,000

## Abstract

PROJECT SUMMARY/ABSTRACT
 Diabetes mellitus (DM) is the leading cause of chronic kidney disease (CKD), accounting for ~47% and
~39% of US incident and prevalent end‐stage kidney disease (ESKD) patients, respectively. Our published
research has shown that hypoglycemia is a highly prevalent complication associated with higher death risk in
diabetic kidney disease (DKD) patients. Diabetic hemodialysis (HD) patients are at heightened risk for
hypoglycemia via multiple pathways, including 1) decreased renal gluconeogenesis, 2) impaired metabolism/
clearance of DM medications, 3) co-existing comorbidities, 4) limited in-center HD food access, and 5) intra-
dialytic glucose shifts. Given the ill effects of hypoglycemia on the cardiovascular (CV) health (arrhythmia,
myocardial ischemia) and psychological well-being (hypoglycemia fear, stress/anxiety) observed in non-CKD
studies, and the poor survival of diabetic HD patients (<35% over 5 years) largely due to CV causes, there is
an urgent unmet need to identify strategies that mitigate low glycemic complications in this population.
 One of the major barriers to optimal glycemic control in DKD has been the lack of access to a practical,
reliable method for frequent glycemic assessment. In diabetic HD patients, conventional metrics (self-
monitored blood glucose [SMBG], HbA1c) are dominantly used despite limitations in accuracy, convenience,
and intermittent frequency. In contrast, continuous glucose monitoring (CGM) is a convenient, automated
glycemic assessment method that has shown improved glycemic control and reduced hypoglycemia in non-
CKD trials. While our pilot data of CGM in HD patients shows strong agreement with gold-standard blood
glucose levels and superior identification of hypoglycemia, it remains uncertain as to whether CGM can
improve glycemic control, reduce hypoglycemia, optimize patient-reported outcomes in this population.
 To address this knowledge gap, we propose this Multiple-PI R01 study in which we aim to conduct a
parallel, two-arm randomized controlled trial (RCT) comparing real-time CGM using Dexcom G6 devices vs.
usual care (SMBG 4-times/day) among 122 in-center HD patients with DM over a 12-week period. Our primary
objective will be to determine the effects of CGM vs. usual care on glycemic control, defined by percent (%) of
time in target glucose range (70-180 mg/dl). Our main and exploratory secondary objectives will be to
determine the effects of CGM on CGM-indices of hypoglycemia, blood-based glycemic markers (HbA1c,
glycated albumin, fructosamine), and patient-reported outcomes (health-related quality of life, diabetes
distress, hypoglycemia fear). We will also evaluate feasibility endpoints by measuring CGM compliance during
the intervention period and success/ease of implementing CGM training sessions among patients. This single-
center pilot RCT is the critical first step in determining the feasibility, efficacy, and safety of CGM in diabetic HD
patients, and it will ...

## Key facts

- **NIH application ID:** 10587470
- **Project number:** 1R01DK132869-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE
- **Principal Investigator:** Kamyar Kalantar-Zadeh
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $314,000
- **Award type:** 1
- **Project period:** 2023-02-01 → 2023-08-27

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10587470

## Citation

> US National Institutes of Health, RePORTER application 10587470, Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial (CONDOR TRIAL) (1R01DK132869-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10587470. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*